Biohaven Ltd. (BHVN) Q2 2021 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Biohaven Ltd..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.209 -- 00:00:05.692 Good morning, and welcome to the BioHaven Pharmaceuticals Q2 2021 00:00:05.692 -- 00:00:10.895 earnings call and webcast. At this time, all participants are in listen-only mode. 00:00:10.895 -- 00:00:14.517 After the speaker's presentation, there will be a question-and-answer session. 00:00:14.517 -- 00:00:18.319 If anyone should require operator assistance, please press star zero on your telephone 00:00:18.319 -- 00:00:22.401 keypad. Please be advised that today's conference call may be recorded. 00:00:22.401 -- 00:00:26.823 I will now hand the conference over to Caroline Dirks from BioHaven. 00:00:26.823 -- 00:00:29.383 Thank you. Please go ahead. 00:00:29.383 -- 00:00:34.846 Thank you, and welcome to the BioHaven second quarter 2021 earnings call. 00:00:34.846 -- 00:00:40.508 Speaking on today's call are Dr. Vlad Chorich, our Chief Executive Officer, Jim Englehart, 00:00:40.508 -- 00:00:45.651 Chief Financial Officer, BJ Jones, Chief Commercial Officer, and Dr. 00:00:45.651 -- 00:00:50.773 Elise Stock, Chief Medical Officer. Earlier this morning, we issued a press release announcing 00:00:50.773 -- 00:00:55.836 the second quarter 2021 highlights. A copy of this press release can be found on our 00:00:55.836 -- 00:00:58.632 website at biohavenpharma.com 00:00:58.632 -- 00:01:02.715 and we will file our Form 10-Q later today. 00:01:02.715 -- 00:01:07.419 Before we begin, let me remind everyone that today's discussion contains forward-looking 00:01:07.419 -- 00:01:13.083 statements based on the environment as we currently see it, and includes risks and uncertainties. 00:01:13.083 -- 00:01:17.826 A list and description of risks and uncertainties associated with an investment in Biohaven 00:01:17.826 -- 00:01:20.468 can be found in t...